NextCell Pharma AB engages in the development of stem cell products. It specializes in the treatment of diabetes and immunosuppression in kidney transplants. The company was founded by Mathias Svahn, Edvard Smith, Hans-Peter Torsten Ekre, and Lena Degling Wilkingsson on March 19, 2014 and is headquartered in Huddinge, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company